1. Academic Validation
  2. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances

Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances

  • Oncotarget. 2016 May 31;7(22):32641-51. doi: 10.18632/oncotarget.8702.
Xiaochuan Liu 1 2 Aoli Wang 2 3 Xiaofei Liang 2 4 Cheng Chen 2 4 Juanjuan Liu 2 3 Zheng Zhao 2 4 Hong Wu 2 3 Yuanxin Deng 2 3 Li Wang 2 4 Beilei Wang 2 4 Jiaxin Wu 2 3 Feiyang Liu 2 3 Stacey M Fernandes 5 Sophia Adamia 5 Richard M Stone 5 Ilene A Galinsky 5 Jennifer R Brown 5 James D Griffin 5 Shanchun Zhang 4 6 Teckpeng Loh 1 Xin Zhang 2 Wenchao Wang 2 4 Ellen L Weisberg 5 Jing Liu 2 4 Qingsong Liu 2 4 7
Affiliations

Affiliations

  • 1 Department of Chemistry, University of Science and Technology of China, Hefei 230036, Anhui, P. R. China.
  • 2 High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, Anhui, P. R. China.
  • 3 University of Science and Technology of China, Hefei 230036, Anhui, P. R. China.
  • 4 CHMFL-HCMTC Target Therapy Joint Laboratory, Hefei 230031, Anhui, P. R. China.
  • 5 Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
  • 6 Hefei Cosource Medicine Technology Co. LTD., Hefei 230031, Anhui, P.R.China.
  • 7 Hefei Science Center, Chinese Academy of Sciences, Hefei 230031, Anhui, P. R. China.
Abstract

PI3Kδ is predominately expressed in leukocytes and has been found overexpressed in B-cell related malignances such as CLL and AML. We have discovered a highly selective ATP competitive PI3Kd inhibitor PI3KD-IN-015, which exhibits a high selectivity among other PI3K isoforms in both biochemical assays and cellular assay, meanwhile did not inhibit most of other protein kinases in the kinome. PI3KD-IN-015 demonstrates moderately anti-proliferation efficacies against a variety of B-cell related Cancer cell lines through down-regulate the PI3K signaling significantly. It induced both Apoptosis and Autophagy in B-cell malignant cell lines. In addition, combination of Autophagy Inhibitor Bafilomycin could potentiate the moderate anti-proliferation effect of PI3KD-IN-015. PI3KD-IN-015 shows anti-proliferation efficacy against CLL and AML patient primary cells. Collectively, these results indicate that PI3KD-IN-015 may be useful drug candidate for further development of anti-B-cell related malignances therapies.

Keywords

B-cell malignances; PI3K; PI3Kδ; kinase inhibitors; leukemia.

Figures
Products